Перегляд за Автор "Skrypnyk, I."
Зараз показуємо 1 - 20 з 119
Результатів на сторінці
Налаштування сортування
Документ Antiulcerogenic effect of lL-arginine of mucous membrane of stomach in experimental ulcer(Programe-Abstract, 2000) Tarasenko, L.; Skrypnyk, I.; Neporada, K.; Скрипник, Ігор Миколайович; Тарасенко, Лідія Мусіївна; Непорада, Каріне СтепанівнаДокумент Application of omeprasole in comprehensive curing of peptic ulcer patients(BMJ, 2000) Skrypnyk, I.; Degitjaryova, I.; Скрипник, Ігор МиколайовичДокумент Diagnostic and Treatment Algorithms of Ulcerative Colitis in Ukraine(KARGER, 2009) Skrypnyk, I.; Скрипник, Ігор МиколайовичQuestions concerning the diagnosis and treatment of ulcerative colitis (UC) in Ukraine are described, in recent years, there has been considerable progress in conservative therapy and new drugs have been developed that provide persistent remission of the inflammatory process after long-term application in many cases. The results of our own investigation on the efficiency of rebamipide in the complex treatment of UC patients are presented. Optimization of treatment with substitution of mesalazine in tablet or granule form, especially with an additional rebamipide prescription and a once-daily administration of budesonide, leads to an increased effectiveness of treatment and improvement of quality of life in UC patients. In the future, development of new approaches in the pharmacotherapy of UC will use medications as a basic therapy with the purpose of achieving high-quality and effective 'convalescence of mucous membrane', including cytoprotectors, bilious acids, endogenous substances, stabilization of membranes, antihypoxantsand correction of microbiocenosis disorders.Документ Doxorubicin-induced arginine/citrulline cycle changes in rat model of non-alcoholic steatohepatitis(Falk Foundation, 2023-05-18) Maslova, G.; Skrypnyk, I.; Lymanets, T.; Skrypnyk, R.; Маслова, Ганна Сергіївна; Скрипник, Ігор Миколайович; Лиманець, Тетяна ВолодимирівнаIntroduction: Doxorubicin (Dox) belongs to the group of anthracycline antibiotics, which are widely used in oncological diseases treatment. The high risk of toxic effects is the basis for studying of the main mechanisms of organs and systems Dox-induced injury development. The aim - to investigate the peculiarities of Dox-induced arginine/citrulline cycle changes in rats with simulated non-alcoholic steatohepatitis (NASH). Methods: The studies were conducted on 30 white non-linear adult rats, weighing 160-220 g. The rats were divided into 3 groups: | (n = 10) - rats (5 males, 5 females), on which NASH was modeled during 63 days, then from the 64th till 66th day they were injected with 1 ml of 0.9% sodium chloride solution intraperitoneally; | (n = 10) - rats (S males, 5 females), on which NASH was modeled during 63 days, continued with Dox injections intraperitoneally 5 mg/kg/day from the 64th till the 66th day; Ill (n = 10) - rats (5 males, 5 females), which received a standard vivarium diet during 63 days, from the 64th to 66th day - 1 ml injections of 0,9% sodium chloride solution intraperitoneally. NASH modeling was hold using a diet containing a 42.8% fats mixture and a 4% fructose aqueous solution. On the 67th day, animals were euthanized under thiopental anesthesia at a dose of 50 mg/kg. A 10% liver homogenate was prepared, in which the concentration of arginine, citrulline, and arginase activity were determined.Документ Erosive and Ulcerative Lesions of Gastroduodenal Zone in Patients with Leukemias: Role of H. pylori(WILEY-BLACKWELL, 2009) Skrypnyk, I.; Maslova, G.; Скрипник, Ігор Миколайович; Маслова, Ганна СергіївнаДокумент Helicobacter pylori and metabolic processe in mucous baller ot gastroduodenal zone peptic ulcer patients in dynamic of the treatmet(EHSG, 2002-09-11) Skrypnyk, I.; Degitjaryova, I.; Скрипник, Ігор МиколайовичДокумент L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia(ООО «МОРИОН», 2017-12) Skrypnyk, I.; Maslova, G.; Lymanets, T.; Gusachenko, I.; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Лиманець, Тетяна ВолодимирівнаДокумент L-arginine – targeted for the anthracycline cardiotoxicity prevention in patients with acute leukemia of high cardiological risk(Annals of Oncology. Official Journal of the European Society for Medical Oncology, 2017) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна СергіївнаThe risk of anthracycline cardiotoxicity (AC) significantly increases in patients with comorbid ischemic heart disease (IHD), which requires monitoring and prevention during chemotherapy (CT) of acute leukemia (AL). Aim: To evaluate the effectiveness of L-arginine in AC prevention in AL patients with comorbid IHD during induction CT. Materials and methods. A total 66 patients with newly diagnosed AL and comorbid IHD were included in the study, ECOG I-II. The cohort consisted of 34 (51.5%) males and 32 (48.5%) females, age 54-72 years. The IHD duration was 3–15 years. CT included doxorubicin. We determined the level of troponin I, nitrite anions [NO2]-, performed daily ECG-monitoring: at baseline and in achieving a cumulative dose of anthracyclines (CDA) from 100 to 200 mg/m2. Depending on AC prevention patients were divided into two groups: (n=36) – AL patients treated with CT; II (n=30) – AL patients treated with CT and L-arginine. Results. Prior to CT, according to the daily ECG-monitoring in 47 (71.2%) patients periods of tachycardia were diagnosed, with single supraventricular extrasystoles (SEs) and ventricular extrasystoles (VEs) – in 35 (53%) and 17 (25.7 %) pts, respectively. The decreased concentration of [NO2]- in blood serum in 1.5 times relative to normal values (p˂0.05) was noticed. Troponin I in all patients of both groups was <0.5 ng/ml. Reaching low CDA in group I we recorded: periods of tachycardia in 36 (100%) pts, increasing number of single and paired SEs – in 24 (66.6%), VEs episodes – in 19 (52%), clinically significant ST-segment depression – in 29 (80.5%) and interval QT prolongation – in 14 (38.8%) pts. Troponin I was >0.5 ng/ml in 7 (19.4%) pts. Simultaneously, deepening of endothelial dysfunction (ED) was noted: [NO2]- was in 1.8 times lower vs norm. After 2 CT courses in 20 (66.6%) patients of group II on tachycardia background the single SEs were recorded and only in 1 (3.3%) patient troponin I level was >0.5 ng/ml. The ED leveled: [NO2]- didn’t significantly differ from the norm. Thus, L-arginine in AL patients with comorbid IHD during induction CT leads to reducing the risk of necrotic injury of cardiomyocytes and improves endothelial function that prevents early AC.Документ L-аргінін у профілактиці антрациклін-індукованого некрозу міокарда у хворих на гострі лейкемії у поєднанні з ішемічною хворобою серця(Вищий державний навчальний заклад України "Українська державна стоматологічна академія", 2017) Скрипник, Ігор Миколайович; Скрыпник, Игорь Николаевич; Skrypnyk, I.; Маслова, Ганна Сергіївна; Маслова, Анна Сергеевна; Maslova, G.; Лиманець, Тетяна Володимирівна; Лыманец, Татьяна Владимировна; Lymanets, T.Кардіотоксична дія антрациклінових антибіотиків (КДАА) характеризується розвитком некротичних змін у кардіоміоцитах, що є одним із найсерйозніших побічних ефектів при лікуванні гострих лейкемій (ГЛ). Хворі із супутньою ішемічною хворобою серця (ІХС) належать до групи високого ризику формування КДАА, що потребує застосування профілактичних засобів. Мета: оцінити ефективність L-аргініну у профілактиці КДАА у хворих на ГЛ із супутньою ІХС в динаміці індукційних курсів ПХТ. Матеріали і методи. Обстежено 66 пацієнтів з вперше виявленими ГЛ (гостра лімфоїдна лейкемія – 7 хворих, гостра мієлоїдна лейкемія – 59) із супутньою ІХС, віком 54–72 роки, з них – 34 (51,5%) чоловіки, 32 (48,5%) – жінки, за ECOG I-II. Тривалість ІХС склала від 3 до 15 років. Схеми ПХТ включали АА. Оцінку антрациклін-індукованого некрозу міокарда проводити шляхом визначення тропоніну І в сироватці крові хворих та проведення добового ЕКГ-моніторингу до початку ПХТ та при досягненні кумулятивної дози антрациклінів (КДА) від 100 до 200 мг/м2. В залежності від проведеної профілактики розвитку КДАА хворі були розподілені на дві групи: І (n=36) – хворі на ГЛ, що отримували ПХТ; ІІ (n=30) – хворі на ГЛ, які отримували ПХТ і L-аргінін на фоні курсів індукції ремісії. Результати. У хворих на ГЛ із супутньою ІХС до початку ПХТ за даними добового ЕКГ-моніторингу, діагностовано періоди тахікардії у 47 (71,2%) хворих, епізоди поодинокої надшлуночкової екстрасистолії (НШЕ) та шлуночкової екстрасистолії (ШЕ) – у 35 (53%) та 17 (25,7%) пацієнтів відповідно, а також короткотривалі періоди депресії сегмента ST, що розвивались за умов збільшення фізичного навантаження. Кардіальні тропоніни І в усіх пацієнтів обох груп були негативні, а саме <0,5 нг/мл. На фоні низьких КДА в І групі періоди тахікардії зафіксовані у всіх 36 (100%) хворих із зростанням кількості поодиноких та групових НШЕ у 24 (66,6%), епізодами ШЕ у 19 (52%), збільшенням кількості клінічно значущої депресії сегмента ST – у 29 (80,5%) і подовженням інтервалу Q-T – у 14 (38,8%) пацієнтів. Біохімічний маркер некрозу міокарда тропонін І був позитивний у 7 (19,4%) хворих І групи і становив >0,5 нг/мл. У ІІ групі за умов проведення профілактики у 20 (66,6%) хворих на фоні тахікардії виявлені епізоди поодинокої НШЕ і лише у 1 (3,3%) хворого був зафіксований позитивний результат тесту на тропонін І в сироватці крові. Отже, призначення L-аргініну у хворих на ГЛ із супутньою ІХС на фоні курсів індукції ремісії приводить до зменшення ризику розвитку некротичного ураження кардіоміоцитів.Документ Pantoprazole and rebamipide provide effective healing of erosive and ulcerative lesions of gastroduodenal zone, associated with helicobacter pylori, in patients with leukemia(Gut. An International Journal of Gastroenterology and Hepatology, 2009) Maslova, G.; Skrypnyk, I.; Скрипник, Ігор Миколайович; Маслова, Ганна СергіївнаДокумент Quality of life in acute leukemia patients with comorbid ischemic heart disease(2018-06-14) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Gusachenko, I.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна СергіївнаДокумент Regylatory peptited as modulators of stressor injuries(GAC, 1998) Tarasenko, L.; Devyatkina, T.; Neporada, K.; Skrypnyk, I.; Korolyova, V.; Vakulenko, S.; Petrushanko, T.; Netukhaylo, L. G.; Скрипник, Ігор Миколайович; Тарасенко, Лідія Мусіївна; Тарасенко, Лідія Мусіївна; Непорада, Каріне Степанівна; Корольова, Владлена Володимирівна; Вакуленко, Світлана Володимирівна; Петрушанко, Тетяна Олексіївна; Нетюхайло, Лілія ГригорівнаДокумент Role of disturbances of the intestinal microbiocenosis of the hepatobiliaris zone diseases(Gut. An International Journal of Gastroenterology and Hepatology, 2009) Skrypnyk, I.; Скрипник, Ігор МиколайовичДокумент Role of Rebamipide in the Therapy of Peptic Ulcer Associated with H. pylori(WILEY-BLACKWELL, 2009) Skrypnyk, I.; Gopko, O.; Vakhnenko, A.; Скрипник, Ігор Миколайович; Гопко, Олександр Феліксович; Вахненко, Андрій ВікторовичДокумент Targeting endothelial dysfunction for protection from anthracycline-induced cardiotoxicity in patients with acute leukemia and co-morbid ischemic heart disease(Hematologica. Journal of the European Hematology Association, 2017) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна СергіївнаCardiotoxicity of chemotherapeutic drugs, in particular anthracycline antibiotics (AA), is one of the biggest problems in treatment of patients with acute leukemia (AL). Chemotherapy with AA is accompanied by systemic endothelial dysfunction, increasing the cardiovascular toxicity risk and promoting vascular complications. Patients with co-morbid ischemic heart disease (IHD) are at extremely high risk of myocardial injury and in need of anthracycline cardiotoxicity (AC) prevention. Aim: To assess the effectiveness of L-arginine in the prevention of endothelial dysfunction as a predictor of acute AC in patients with AL and co-morbid ischemic heart disease. Materials and methods. A total of 66 patients with newly diagnosed acute leukemia (acute lymphoid leukemia – 7 patients, acute myeloid leukemia – 59 patients) and co-morbid ischemic heart disease were included in the study. The cohort consisted of 34 (51.5%) males and 32 (48.5%) females, age of 54–72 years, ECOG I-II. The duration of IHD ranged from 3 to 15 years. Chemotherapy (CT) schemes included AA (doxorubicin). The evaluation of endothelial dysfunction was performed by determining the stable metabolites of nitric oxide – nitrite anions [NO2]- and activity of total NO-synthase in serum of patients before the CT and upon reaching a cumulative dose of AA from 100 to 200 mg/m2 by doxorubicin. The mean total cumulative dose of AA reached 162,04±24,65 mg/m2 and 166,49±27,34 mg/m2 in groups I and II respectively. The study was approved by the local ethical committee and all patients gave a written consent before they were included in the study. Patients were divided into two groups: (n=36) – AL patients treated with CT; II (n=30) – AL patients, whom during the CT in order for prevention of acute AC were given L-arginine hydrochloride 4.2% 100 ml IV the day before and during administration of AA, followed by oral L-arginine aspartate for a month. Results. In the debut of AL prior to the CT in all 66 (100%) patients the increased activity of total NOS in 3.8 times compared with the norm (p˂0,001) was noted, with simultaneously reduced concentration of [NO2]- in 1.5 times relatively normal values (p˂0,05) (Table 1). As a result of two CT courses of remission induction in patients of group I the tendency to reduce the total NOS activity compared with its level before treatment was observed. At the same time the significant decrease of [NO2]- in 1.8 times relatively normal values (p <0.01) and a trend to lower their content in 1.2 times compared with the data before treatment (p>0.05) was noted. These changes constitute the violation of NO-dependent vasodilation mechanism and endothelial dysfunction intensification. Provided achieving low cumulative dose of AA in patients of group II on the background of AC prevention with L-arginine showed a significant decrease in 1.9 times the total NOS activity (p <0.001) with a simultaneous tendency to increase concentration of [NO2]- in 1.3 times (p>0.05) compared to that before treatment. Thus, during the CT with the inclusion of AA without L-arginine in patients with AL and co-morbid IHD we observed the depletion of NO substrate production, accompanied by endothelial dysfunction impairment. The additional appointment of L-arginine on the background of CT can restore synthesis of NO and, respectively, the mechanism of NO-dependent vasodilation, thus reducing the risk of early anthracycline cardiotoxicity development.Документ The effect of body weight and psychological characteristics on periodontal disease development(Folia Medica, 2023-10-31) Skrypnyk, M.; Petrushanko, T.; Neporada, K.; Vynnyk, N.; Skikevych, M.; Skrypnyk, I.; Скрипник, Максим Ігорович; Петрушанко, Тетяна Олексіївна; Непорада, Каріне Степанівна; Винник, Наталія Іванівна; Скікевич, Маргарита Георгіївна; Скрипник, Ігор МиколайовичThe aim of the study was to examine the association between periodontal health in young patients with various body mass indexes and psychological traits such as temperament, level of anxiety, and autonomic nervous system tone.Документ The free radical oxidation role in the development of anthracycline-induced cardiotoxicity in patients with acute leukemia in the presence of concomitant ischemic heart disease(Hematologica. Journal of the European Hematology Association, 2015) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна СергіївнаAnthracycline antibiotics (AA) are included into the most modern acute leukemia (AL) treatment regimens. The AA assignment in polychemotherapy (PCT) programs contributes to the clinical-hematological remission percentage growth, and the improvement of pts survival. However, the formation of anthracycline-induced cardiotoxic effects can be significant limiting factor of PCT full dose conducting, which certainly leads to reduced effectiveness of anticancer therapy. In this aspect particularly important becomes the assessment of the heart tissue injuries potential risks. The incidence of cardiotoxicity depends on the cumulative dose (CD) of AA. The generally toxic AA CD is 550 mg/m2 for doxorubicin. An additional risk factor for anthracycline cardiotoxicity is considered to be the concomitant ischemic heart disease (IHD). The imbalance between generation and inactivation mechanisms of aggressive free radicals as a risk factor of heart tissue AA-induced injury in patients with AL with concomitant ischemic heart disease remain insufficiently studied. The aim – To assess the prooxidant-antioxidant imbalance status in pts with AL in the dynamics of AA treatment taking into account concomitant IHD. Methods: The study involved 41 patients with acute leukemia (acute lymphoblastic leukemia - 13 pts, acute myeloid leukemia - 28 pts), aged 16–72 years, 23 (56%) men and 18 (44%) women, which PCT included AA. Patients were divided into two groups according to the presence of concomitant IHD: I (n=24) – without concomitant IHD; II (n=17) – with the concomitant IHD. The general condition assessment of pts of the both groups was performed twice: before specific therapy and after reaching AA cumulative dose from 100 to 200 mg/m2. The POL processes activity was determined by the malondialdehyde (MDA) level, the antioxidant protection (AOP) – the serum catalase concentration. Results Before treatment in patients of group I without concomitant IHD the MDA concentration in serum exceeded the upper limit of normal in 1.2 times, the catalase level – in 1.1 times. In patients of group II with concomitant IHD the MDA level was increased in 1.46 times with the simultaneous tendency to reduce the catalase concentration in serum compared to normal, indicating that the exhaustion of antioxidant protection on the IHD background. Upon reaching the AA CD of 100-200 mg/m2 MDA concentration in serum was in 1.54 times higher in pts of group II compared with pts of group I (4.81 ± 0.38 mmol/l vs 3.12 ± 0.28 mmol/l; p <0.05). Simultaneously, with the presence of concomitant IHD in pts of group II the catalase level in serum was in 2.1 times lower in comparison with pts of group I (72.5 ± 8.7 mkkat/l vs 33.8 ± 3.2 mkkat/l; p <0.05). Therefore, concomitant IHD in patients with AL during the treatment AA is an additional risk factor for cardiotoxicity, due to exhaustion antioxidant protection system and deepening imbalance between the formation and inactivation of free radicals.Документ The role of daily ECG-monitoring in the myocardial injury diagnosis on the background of anthracycline low cumulative doses in patients with acute leukemia in combination with ischemic heart disease(Hematologica. Journal of the European Hematology Association, 2016) Lymanets, T.; Skrypnyk, I.; Maslova, G.; Скрипник, Ігор Миколайович; Маслова, Ганна Сергіївна; Лиманець, Тетяна ВолодимирівнаAnthracycline-induced cardiotoxicity is a complicated problem of treating patients with acute leukemia (AL), which can lead to the acute cardiac events development. Ischemic heart disease (IHD) is one of the cardiotoxicity risk factors, which requires monitoring of changes in myocardial bioelectric activity on the background of anthracycline low cumulative doses (CDs) in these patients. Aim: To assess the nature of electrocardiogram (ECG) changes on the background of anthracycline low CDs in patients with AL taking into account concomitant ischemic heart disease. Materials and methods. The study involved 93 patients with newly diagnosed AL (acute lymphoblastic leukemia – 21 pts, acute myeloid leukemia – 72 pts), mean age 16-72 years, 48 (51.8%) men, 45 (48.2%) women, ECOG I-II. Their polychemotherapy (PCT) programs included anthracyclines. According to the presence of concomitant IHD patients were divided into two groups: I (n=57) – AL patients without concomitant IHD; II (n=36) – AL patients with concomitant IHD. The standard 12-lead ECG and daily ECG-monitoring were performed for patients of both groups in achieving the CD from 100 to 200 mg/m2 for doxorubicin, which amounted 179.5 ± 24.11 mg/m2 and 172.1 ± 23.15 mg/m2 in patients of groups I and II respectively. Results. The sinus tachycardia, repolarization processes violations and QRS complex voltage reduction were registered in 16 (28%) pts of group I according to the standard 12-lead ECG. In 29 (80.5%) pts of group II on the sinus tachycardia background the following changes were revealed: right bundle branch block – in 2 (5.6%) pts, left anterior fascicular block – in 2 (5.6%) pts, first-degree atrioventricular block – in 2 (5.6%) pts, supraventricular extrasystoles – in 4 (11.1%) pts, lower voltage and repolarization processes reduction – in 8 (22.2%) pts. The ST segment depression was registered in 13 (36.1%) pts, the Q-T interval prolongation – in 6 (16.6%) pts, T wave changes – in 6 (16.7%) pts of group II. According to the daily ECG-monitoring in 28 (49%) pts of group I with minimal physical activity on the tachycardia background the episodes of solitary supraventricular extrasystoles were detected. In all 36 (100%) patients of group II the periods of tachycardia were recorded, that were accompanied by the increasing number of single supraventricular extrasystoles, episodes of paired and group supraventricular extrasystoles – in 24 (66.6%) pts, single episodes of ventricular extrasystoles – in 19 (52%) pts and increased number of clinically significant ST segment depression periods – in 29 (80.5%) and Q-T prolongation – in 14 (38.8%) patients. Low CDs up to 100-200 mg/m2 for doxorubicin in AL patients without ischemic heart disease are accompanied by the cardiotoxic effects development in the form of arrhythmias: sinus tachycardia, supraventricular extrasystoles. In case of concomitant ischemic heart disease presence the complex of myocardial bioelectric activity disorders develops, such as arrhythmias, conduction abnormalities and silent myocardial ischemia. With the purpose of early anthracycline-induced cardiotoxicity diagnosis in patients with AL receiving PCT it is necessary to conduct daily ECG-monitoring, which has greater sensitivity compared with standard 12-lead ECG.Документ Ursodeoxycholic acid and ademethionine as an effective combination for the anthracycline-induced liver injury treatment(Gut. An International Journal of Gastroenterology and Hepatology, 2012) Skrypnyk, I.; Maslova, G.; Lymanets, T.; Скрипник, Ігор Миколайович; Лиманець, Тетяна Володимирівна; Маслова, Ганна СергіївнаThe primary method of acute leukemia treatment is the program polychemotherapy (PCT), including anthracycline antibiotics. Liver injuries on the PCT background are the limiting factor for the PCT in its entirety. The anthracycline antibiotics use is associated with the risk of drug-induced liver injury (DILI) development. The aim of study is to improve the effectiveness of treatment of the anthracycline-induced DILI through the development of new pharmacological complexes. We examined 54 patients with acute myeloid leukemia, who developed DILI in the PCT dynamics. Results: The increased alkaline phosphatase (ALP) activity, gamma-glutamyl transpeptidase (GGT), bilirubin, ALT, AST was found on the PCT background compared with healthy. While the argynase blood activity decreased and the concentration of the average weight molecules (AWM) increased. After 30 days of treatment the ALP, GGT, total bilirubin, ALT and AST activity decreased. At the 56th -60th days of treatment the cytolytic and cholestatic syndromes parameters normalized in 44 (81.5%) pts. The argynase activity increased on the background of decreased the AWM level, reflecting the increased detoxication processes. This allows conducting PCT in full compliance with cytostatics administration regimen. Conclusion: Thus, the combination of UDCA and ademethionine in high doses is optimal approach to treatment and prevention of DILI, induced by anthracyclines.Документ Адаптація до коротких стресорних впливів як фактор підвищення стійкості пародонта до гострого стресу(Вищий державний навчальний заклад України «Українська медична стоматологічна академія», 2003) Тарасенко, Лідія Мусіївна; Петрушанко, Тетяна Олексіївна; Непорада, Каріне Степанівна; Скрипник, Ігор Миколайович; Тарасенко, Лидия Моисеевна; Петрушанко, Татьяна Алексеевна; Непорада, Каринэ Степановна; Скрыпник, Игорь Николаевич; Tarasenko, L.; Petrushanko, T.; Neporada, K.; Skrypnyk, I.Експериментально обгрунтований стреспротективний ефект адаптації до коротких стресових впливів в залежності від статі і типу поведінкової реакції тварин щодо соматичних змін і деструктивних процесів в тканинах пародонта в умовах дії гострого стресу; Экспериментально обоснован стресспротективный эффект адаптации к коротким стрессорным влияниям в зависимости от пола и типа поведенческой реакции животных в отношении соматических изменений и деструктивных процессов в тканях пародонта в условиях действия острого стресса; It was based in experiment a stress-protective effect of adaptation to short-term stresses on somatically changes and destructive processes under the acute stress depending on the sex and the type of behavioral activity of animals